No significant difference in overall survival was seen between treatment groups , with 303 deaths ( 83.7 % ) in the everolimus group and 151 deaths ( 82.1 % ) in the placebo group ( hazard ratio [ HR ] , 1.05 ; 95 % CI , 0.86-1 .27 ; P = .68 ; median overall survival , 7.6 months with everolimus , 7.3 months with placebo ) .